SCHEMBL25647154

SCHEMBL25647154

O=C1CCC(N2C(=O)c3ccc(CN4CC5CCC4CN5)cc3C2=O)C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 19/20 0.54
▸ DDB1 Q16531 16/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ CHRM2 P08172 1/20 0.54
▸ OPRM1 P35372 1/20 0.54
▸ IKZF3 Q9UKT9 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ GSPT1 P15170 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25647153 0.92 CRBN (0.54) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL25646994 0.84 CRBN (0.55) CRBNDDB1IKZF3GSPT1
SCHEMBL31077418 0.82 DDB1 (0.59) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL30351350 0.81 CRBN (0.61) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL30798910 0.81 CRBN (0.58) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL31077539 0.81 CRBN (0.58) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL25647152 0.81 CRBN (0.58) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL25647151 0.81 CRBN (0.58) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL31055237 0.81 CRBN (0.51) CRBNDDB1ALDH1A1CHRM2OPRM1
SCHEMBL30458550 0.80 CRBN (0.53) CRBNDDB1ALDH1A1CHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP claimed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 — — WO disclosed
Send feedback